Press release 10 November 2010

IFPMA announces Amgen as new member company

Press release

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Amgen has become its newest member company.

IFPMA Director General Eduardo Pisani said: “Amgen is a major force in the increasingly significant biotech sector and is therefore an important and welcome addition to the IFPMA. Amgen will provide us with new perspectives on emerging issues and, I hope, the IFPMA’s experience in dealing with global issues will be able to help Amgen as it expands its geographical presence.”

A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. Amgen’s headquarters are in Thousand Oaks, California, USA. For general information on Amgen, please go to

For details of the company’s corporate citizenship activities, please go to

Washington DC, 10 November 2010


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster